Small benchtop fluorescent immunoassay analyzer
Sofia 2 uses fluorescent technology to deliver automated, objective, and accurate test results in three to 15 minutes. Sofia 2 is a small benchtop fluorescent immunoassay analyzer with flexible workflows to accommodate any laboratory environment and testing volume. Results store automatically on Sofia 2 and can optionally be exported, printed, sent directly to your LIS, or viewed remotely with Quidel’s secure, HIPAA-compliant Virena data management system. The Sofia 2 menu of CLIA-waived assays includes Sofia Influenza A+B FIA, Sofia RSV FIA, Sofia Strep A+ FIA, and Sofia 2 Lyme FIA. Quidel
Influenza A & B 2 assay
ID NOW, a CLIA-waived point-of-care molecular platform, is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The Influenza A & B 2 assay on the ID NOW platform delivers point-of-care molecular detection and differentiation of influenza A and B virus in 13 minutes or less, with early call out of positive results in as little as five minutes. The Strep A 2 assay provides molecular detection of Group A Streptococcus bacterial nucleic acid—in six minutes or less, positive results displayed as early as two minutes—with no culture confirmation required for negative results. Abbott
Pathogen ID from pure culture
Quickly deliver actionable results to clinicians to support informed treatment decisions with VITEK MS. The expanded database version 3.2 includes 1,316 claimed and unclaimed species and subspecies. Simple, safe, and effective protocols offer excellent performance for the identification of Mycobacteria, Nocardia, and molds. VITEK MS is an in-lab solution that can help save time and cost compared to sending out tests or using other identification methods. bioMérieux, Inc.
Collect and report ID/AST results
Beckman Coulter’s DxM Trio of microbiology systems brings together the speed of mass spectrometry with the Bruker MALDI Biotyper,* the accuracy of the DxM MicroScan WalkAway system, united by LabPro-MBT to efficiently collect and report ID/AST results through a single software. Together, this integrated solution of technologies streamlines processes to enhance performance and stewardship while reducing treatment delays for improved patient management. *MALDI Biotyper is the property of Bruker Daltonik GmbH. Beckman Coulter
